Skip to content

Observational Clinical Study on the Impact of Tumor Immune Microenvironment Heterogeneity on Treatment Efficacy in Young-Onset Colorectal Cancer Patients

Observational Clinical Study on the Impact of Tumor Immune Microenvironment Heterogeneity on Treatment Efficacy in Young-Onset Colorectal Cancer Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111900
Enrollment
Unknown
Registered
2025-11-07
Start date
2025-11-10
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with stage I-III surgically resectable colon cancer

Interventions

Patients with young-onset colorectal cancer (YO-CRC group):None
Patients with late-onset colorectal cancer(LO-CRC group):None

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily sign the informed consent form; 2.Aged 18-50 and 65-80 years; 3.Patients with stage I-III resectable colon cancer confirmed by NCCN guideline; 4.Colectomy and regional lymph node dissection are required according to the judgment of the treating doctor; 5.All patients were treated with standard protocols; 6.Tolerated electronic colonoscopy.

Exclusion criteria

Exclusion criteria: 1.Neurological or psychiatric abnormalities that affect cognitive ability; 2.Patients with other primary tumors; 3.Presence of severe systemic disease; 4.It is judged by the investigator to be unsuitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Overall survival;

Secondary

MeasureTime frame
Progression-free survival;

Countries

China

Contacts

Public ContactYuan Fang

Southern Medical University Southern Hospital

fangyuan1313@163.com+86 15626435156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026